Taimed Biologics Inc.TPEX: 4147

2022 general shareholders' meeting approved the lifting of non-competition restrictions for directors

· Issued by TaiMed Biologics Inc.
Close
Today's Information

Provided by: TaiMed Biologics Inc.
SEQ_NO 6 Date of announcement 2022/05/30 Time of announcement 15:50:10
Subject
 2022 general shareholders' meeting approved the
lifting of non-competition restrictions for directors
Date of events 2022/05/30 To which item it meets paragraph 21
Statement
1.Date of the shareholders' meeting resolution:2022/05/30
2.Name and title of the managerial officer with permission
 to engage in competitive conduct:
 (1) Director: Frank Chen(Representative of Chang Chun Investment)
 (2) Director: Tien-Chieh, Lee(Representative of Huei Hong Investment)
 (3) Director: Tamon Tseng(Representative of Yi Tai Investment)
 (4) Director: Shih Chia Lin(Representative of National Development Fund)
 (5) Independent director:Howard S. Lee
 (6) Institutional director:National Development Fund
3.Items of competitive conduct in which the officer is
permitted to engage:
 Investing in or managing a third party operating in a scope of business
 similar to that of the Company
4.Period of permission to engage in the competitive conduct:
 For the duration of serving as a director of the Company
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
 The proposal has been passed as is by a two thirds vote of the
 shareholders present in a meeting attended by shareholders representing
 a majority or more of the shares outstanding.
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter "N/A" below):N/A
7.Company name of the mainland China enterprise and the
officer's position in the enterprise:N/A
8.Address of the mainland China enterprise:N/A
9.Operations of the mainland China enterprise:N/A
10.Impact on the company's finance and business:None
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:N/A
12.Any other matters that need to be specified:None

Earlier from Taimed Biologics

All Taimed Biologics news releases